ACADIA Pharmaceuticals Inc. (ACAD) is listed on NASDAQ in Pharmaceutical Stocks. It is $29.12, -2.05%, with a $5.0B market cap. RSI is 56.8, neutral. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 56.8 Neutral
Market Cap $5.0B
Volume 1.1M
Fundamentals — 10-Q Q2 2026
Revenue $576.0M
Net Income $35.1M
EPS $0.20
Gross Margin 90.8%
Operating Margin 5.8%
Net Margin 6.1%
P/E Ratio 145.6x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 20,141 | $29.16 | $587,242 | 2026 Aug 6 |
| Thompson Elizabeth H.z. | EVP, Head of Research & Dev | Sell | 16,558 | $26.13 | $432,663 | 2026 Jul 30 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 11,421 | $26.08 | $297,912 | 2026 Jun 26 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 5,401 | $21.18 | $114,393 | 2026 May 26 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,332 | $21.79 | $29,024 | 2026 May 4 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,506 | $21.79 | $76,396 | 2026 May 4 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 2,709 | $22.20 | $60,140 | 2026 Apr 7 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,030 | $22.20 | $22,866 | 2026 Apr 7 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,942 | $21.57 | $41,895 | 2026 Mar 26 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 7,385 | $21.55 | $159,136 | 2026 Mar 26 |
| Owen Adams Catherine | Chief Executive Officer | Sell | 11,641 | $21.47 | $249,932 | 2026 Mar 25 |
| Thompson Elizabeth H.z. | EVP, Head of Research & Dev | Sell | 3,435 | $21.47 | $73,749 | 2026 Mar 25 |
| Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | Sell | 3,844 | $21.47 | $82,531 | 2026 Mar 25 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,084 | $23.69 | $96,750 | 2025 Nov 18 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 10,262 | $23.69 | $243,107 | 2025 Nov 18 |
| Daly James M | Director | Sell | 30,000 | $22.37 | $671,100 | 2025 Nov 10 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,498 | $23.65 | $82,728 | 2025 Sep 15 |
| Garofalo Elizabeth A. | Director | Sell | 1,600 | $25.98 | $41,568 | 2025 Sep 2 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 22,000 | $25.18 | $553,960 | 2025 Aug 18 |
| Brege Laura | Director | Sell | 14,446 | $21.78 | $314,634 | 2025 Jun 4 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $25.07 | 48.2 | $4.7B |
| | $98.02 | 39.9 | $4.1B |
Take ACAD further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put ACAD in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when ACADIA Pharmaceuticals Inc. next reports.
Set alerts on ACAD
Get notified when ACADIA Pharmaceuticals Inc. hits your price targets or technical conditions are met.
Get Started Free